

Protalix BioTherapeutics, Inc.  
Form 8-K  
June 13, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): June 13, 2014**

**Protalix BioTherapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**



**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On June 13, 2014, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing that David Aviezer, Ph.D., has decided to retire after almost 12 years from his role as the Company’s President and Chief Executive Officer. He will retire this year upon the completion of a process to nominate his successor. In the meantime, Dr. Aviezer will continue serving as President and Chief Executive Officer and remains a member of the Board of Directors. A copy of the press release is filed as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1 Press release dated June 13, 2014

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROTALIX BIOTHERAPEUTICS, INC.**

Date: June 13, 2014 By: /s/ David Aviezer, Ph.D.

Name: David Aviezer, Ph.D.

Title: President and Chief Executive Officer